Lifesci Capital Issues Pessimistic Outlook for RAPT Earnings

Rapt Therapeutics (NASDAQ:RAPT) – Investment analysts at Lifesci Capital reduced their FY2026 earnings estimates for Rapt Therapeutics in a research report issued to clients and investors on Monday, October 20th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings per share of ($1.60) for the year, down from their prior estimate of ($1.58). Lifesci Capital currently has a “Strong-Buy” rating and a $31.00 price target on the stock. The consensus estimate for Rapt Therapeutics’ current full-year earnings is ($2.14) per share.

Rapt Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.04).

A number of other equities analysts also recently issued reports on the stock. Leerink Partnrs raised shares of Rapt Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. JPMorgan Chase & Co. raised shares of Rapt Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $13.00 to $55.00 in a report on Monday. Wells Fargo & Company reaffirmed an “overweight” rating and set a $48.00 price target (up previously from $38.00) on shares of Rapt Therapeutics in a report on Tuesday. UBS Group set a $9.00 price target on shares of Rapt Therapeutics and gave the company a “neutral” rating in a report on Tuesday, August 12th. Finally, Leerink Partners raised shares of Rapt Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $16.00 to $37.00 in a report on Friday, September 26th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

Rapt Therapeutics Trading Down 10.5%

RAPT opened at $30.00 on Thursday. The company has a market cap of $496.20 million, a price-to-earnings ratio of -2.12 and a beta of 0.23. The company’s 50 day moving average is $19.90 and its 200 day moving average is $12.40. Rapt Therapeutics has a 12-month low of $5.67 and a 12-month high of $42.39.

Institutional Investors Weigh In On Rapt Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Comerica Bank raised its position in shares of Rapt Therapeutics by 53.9% during the first quarter. Comerica Bank now owns 89,327 shares of the company’s stock valued at $109,000 after buying an additional 31,287 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Rapt Therapeutics during the first quarter valued at approximately $188,000. Invesco Ltd. raised its position in shares of Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock valued at $72,000 after buying an additional 47,391 shares during the last quarter. Nuveen LLC bought a new stake in shares of Rapt Therapeutics during the first quarter valued at approximately $143,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Rapt Therapeutics by 112.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company’s stock valued at $184,000 after buying an additional 79,967 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.